These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23174141)

  • 1. Nanocarriers for the targeted treatment of ovarian cancers.
    Tomasina J; Lheureux S; Gauduchon P; Rault S; Malzert-Fréon A
    Biomaterials; 2013 Jan; 34(4):1073-101. PubMed ID: 23174141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The holistic 3M modality of drug delivery nanosystems for cancer therapy.
    Sun J; Luo C; Wang Y; He Z
    Nanoscale; 2013 Feb; 5(3):845-59. PubMed ID: 23292001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-specific intracellular anticancer drug delivery from mesoporous silica nanoparticles with pH sensitivity.
    Luo Z; Cai K; Hu Y; Zhang B; Xu D
    Adv Healthc Mater; 2012 May; 1(3):321-5. PubMed ID: 23184747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymeric drug delivery systems for localized cancer chemotherapy.
    De Souza R; Zahedi P; Allen CJ; Piquette-Miller M
    Drug Deliv; 2010 Aug; 17(6):365-75. PubMed ID: 20429844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
    Santin AD; Cané S; Bellone S; Palmieri M; Siegel ER; Thomas M; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
    Cancer Res; 2005 May; 65(10):4334-42. PubMed ID: 15899825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis.
    Hamelers IH; Staffhorst RW; Voortman J; de Kruijff B; Reedijk J; van Bergen en Henegouwen PM; de Kroon AI
    Clin Cancer Res; 2009 Feb; 15(4):1259-68. PubMed ID: 19228729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels.
    Zahedi P; Stewart J; De Souza R; Piquette-Miller M; Allen C
    J Control Release; 2012 Mar; 158(3):379-85. PubMed ID: 22154933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
    Markman M
    Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micro- and nanocapsules: a lively field of research.
    van Hest JC
    Macromol Biosci; 2010 May; 10(5):463-4. PubMed ID: 20401900
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.
    Orr JW; Orr P; Kern DH
    Cancer J Sci Am; 1999; 5(3):174-8. PubMed ID: 10367175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifunctional nanocarriers for simultaneous encapsulation of hydrophobic and hydrophilic drugs in cancer treatment.
    Su CW; Chiang CS; Li WM; Hu SH; Chen SY
    Nanomedicine (Lond); 2014 Jul; 9(10):1499-515. PubMed ID: 25253498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smart multilayered assembly for biocompatible siRNA delivery featuring dissolvable silica, endosome-disrupting polycation, and detachable PEG.
    Suma T; Miyata K; Anraku Y; Watanabe S; Christie RJ; Takemoto H; Shioyama M; Gouda N; Ishii T; Nishiyama N; Kataoka K
    ACS Nano; 2012 Aug; 6(8):6693-705. PubMed ID: 22835034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified double-emulsion method for the preparation of daunorubicin-loaded polymeric nanoparticle with enhanced in vitro anti-tumor activity.
    Liu J; Qiu Z; Wang S; Zhou L; Zhang S
    Biomed Mater; 2010 Dec; 5(6):065002. PubMed ID: 20924138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the management of women with ovarian cancer.
    Eltabbakh GH
    Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New options for the treatment of advanced ovarian cancer.
    Dunton CJ
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of targeted therapies in ovarian cancer.
    Banerjee S; Gore M
    Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of pemetrexed in ovarian cancer.
    Tomao F; Panici PB; Frati L; Tomao S
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1727-35. PubMed ID: 19954283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.